Cara Therapeutics, Inc. - Common Stock (CARA)

Cara Therapeutics is a biopharmaceutical company focused on developing innovative therapies for pain and pruritus, utilizing its proprietary technology to create selective kappa opioid receptor agonists

The company's research aims to address unmet medical needs in various conditions, including chronic pain and inflammatory diseases, by leveraging its scientific expertise to discover and advance new treatment options. Through its commitment to improving patient outcomes, Cara Therapeutics seeks to transform the way pain and related symptoms are managed in healthcare settings.